Company profile
Nascent Biotech, Inc.
OTC: NBIO · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 26GM —SS 30
v0.1 · 25/100 weight · pillars only
↑ listing tenure, growth stability · ↓ revenue growth (YoY), Piotroski F
Methodology →Revenue TTM
$3
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$2.1M
Employees
2
as of 2026-08-28
Market cap
$51.7k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income-$2.1M-$2.1M2024
Operating income-$2.2M-$2.2M2024
Total assets$552.1k$552.1k2024
Liabilities$808.8k$808.8k2024
Equity-$256.7k-$256.7k2024
Revenue trend
FY2017 – FY2023 · USD
FY17
FY20
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Nascent Biotech, Inc.’s revenue?
Nascent Biotech, Inc. booked $0 in FY2023 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Manhattan Scientifics, Inc.——Mera Pharmaceuticals, Inc.——Hero Technologies Inc.——SOAFEE, Inc.——Nunzia Pharmaceutical Company——Bright Green Corporation——Neighbors
Indian River →Key facts
CEOSean Carrick
SectorHealthcare
IndustryBiotechnology
HeadquartersVero Beach, FL
ExchangeOTC: NBIO
Employees2
IPO date2009-12-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.